XML 33 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Intangible Assets
 6 Months Ended
Jun. 27, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
 
 
December 31,
2019
 
Purchase accounting adjustments
 
Business acquisitions
 
Business divestitures
 
Currency translation adjustments
 
June 27,
2020
CSCA
 
$
1,899.1

 
$
(10.4
)
 
$
14.6

 
$
—

 
$
(4.1
)
 
$
1,899.2

CSCI(1)
 
1,203.7

 
12.0

 
1.7

 
(115.6
)
 
(11.3
)
 
1,090.5

RX(2)
 
1,013.9

 
—

 
—

 
—

 
0.6

 
1,014.5

Total goodwill
 
$
4,116.7

 
$
1.6

 
16.3

 
$
(115.6
)
 
$
(14.8
)
 
$
4,004.2



(1) We had accumulated goodwill impairments of $868.4 million as of each of December 31, 2019 and June 27, 2020.
(2) We had accumulated goodwill impairments of $109.2 million as of each of December 31, 2019 and June 27, 2020.

During the three months ended June 27, 2020, our BCS reporting unit had an indication of potential impairment which was driven by a decrease in forecasted cash flows in the second half of 2020 related to impacts from the COVID-19 pandemic. Goodwill remaining in this reporting unit was $961.0 million as of June 27, 2020. We prepared an impairment test as of June 27, 2020 and determined that the fair value of the BCS reporting unit exceeded net book value by less than 10%, consistent with our last annual impairment test as of October 1, 2019. While no impairment was recorded as of June 27, 2020, future developments such as deterioration in business performance or market multiples could reduce the fair value of this reporting unit and lead to impairment in a future period.

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):
 
June 27, 2020
 
December 31, 2019
 
Gross
 
Accumulated
Amortization
 
Gross
 
Accumulated
Amortization
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
3.8

 
$
—

 
$
18.8

 
$
—

In-process research and development
38.5

 
—

 
50.0

 
—

Total indefinite-lived intangibles
$
42.3

 
$
—

 
$
68.8

 
$
—

Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements and supply agreements
$
133.4

 
$
81.1

 
$
126.7

 
$
81.1

Developed product technology, formulations, and product rights
1,306.9

 
709.1

 
1,392.8

 
755.3

Customer relationships and distribution networks
1,821.0

 
727.7

 
1,805.6

 
671.4

Trademarks, trade names, and brands
1,421.9

 
285.7

 
1,353.5

 
250.1

Non-compete agreements
5.1

 
4.9

 
6.5

 
6.0

Total definite-lived intangibles
$
4,688.3

 
$
1,808.5

 
$
4,685.1

 
$
1,763.9

Total intangible assets
$
4,730.6

 
$
1,808.5

 
$
4,753.9

 
$
1,763.9



We recorded amortization expense of $72.2 million and $145.4 million for the three and six months ended June 27, 2020, respectively, and $73.6 million and $149.0 million for the three and six months ended June 29, 2019, respectively.
Generic Product

During the three months ended June 29, 2019, we identified impairment indicators for a certain definite-lived intangible asset related to changes in pricing and competition in the market, which lowered the projected cash flows we expect to generate from the asset. We recorded an asset impairment of $27.8 million in our RX segment.

In-process R&D ("IPR&D")

We recorded an impairment charge of $4.1 million on a certain IPR&D asset during the six months ended June 29, 2019, due to changes in projected development and regulatory timelines for a product in our CSCA segment.